The present invention relates to compounds corresponding to formula (I) in which: —R1 represents a substituted phenyl; —R2 represents: —a substituted phenyl; —a heteroaromatic group, the said group being unsubstituted or substituted one or more times; —R3 represents a group Alk; —R4 represents a hydrogen atom or a (C1-C4)alkyl; —R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; —or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; —R6 represents a group —COOAlk, a group —CONH2 or a group —NHSO2Alk; —Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use.
本发明涉及与式(I)相对应的化合物,其中:
—R1代表取代的苯基;
—R2代表:
—取代的苯基;
—杂环芳基,该基团未取代或取代一次或多次;
—R3代表Alk基团;
—R4代表氢原子或(C1-C4)烷基;
—R5代表氢原子,(C3-C6)环烷基或(C1-C4)烷氧基-Alk;
—或者R4和R5与它们附着的氮原子一起构成从以下选择的杂环基团:氮杂环丙基-1-yl,
吡咯烷基-1-yl,
哌啶基-1-yl,吗啉-4-yl;
—R6代表—COOAlk基团,—CONH2基团或—NHSO2Alk基团;
—Alk代表(C1-C4)烷基,该基团未取代或取代一次或多次,其中含有卤素原子;
以碱式或酸加成盐的形式。制备过程以及诊断和治疗用途。